Cambridge Healthtech Associates to deliver research on market opportunity for pre-clinical assay. Assay will evaluate potential toxicity in drug candidates

NEEDHAM, Massachusetts and SCARBOROUGH, Ontario – April 5, 2012 – Cambridge Healthtech Associates™ (CHA™) and Nucro-Technics, a full-service Contract Support Organization, today announced a new partnership focused on a market evaluation of a new biomarker tool set to predict safety adverse events. The goal is develop a novel pre-clinical, fee-for-service assay for use in the evaluation of the potential toxicity of new drug candidates.

“We see this project as an opportunity to explore a new and exciting program that will help our clients make informed decisions about bringing new drug candidates to market,” said Bedrich Videl, Special Projects, at Nucro-Technics, “We are continually striving to provide new products that meet the needs of the biopharmaceutical industry.”

CHA will conduct interviews with leaders in the pharmaceutical and biotech industries to gain an understanding of the current market landscape in drug safety biomarkers, assess the market needs and priorities on drug safety and biomarkers, and examine how the safety screening field is evolving.

“We are looking forward to this research project,” said Dr. Ernie Bush, Scientific Director, at CHA. “Helping clients like Nucro-Technics assess the market’s interest in drug safety biomarkers is essential to understanding the status of this technology, and the optimal ways of moving forward to gain benefit for the pharma industry and patient health.”

About Cambridge Healthtech Associates
Cambridge Healthtech Associates™ (CHA™) uses its unique collaborative model to improve the speed, economics and effectiveness of life science research and development, leveraging its consulting, technology evaluations and communities to help clients in the industry achieve their individual goals. Read more at www.chacorporate.com.

Cambridge Healthtech Associates also manages the Drug Safety Executive Council™ (DSEC™) a community of drug safety professionals focused on the development of better and safer medicines and can be found at www.drugsafetycouncil.org.

About Nucro-Technics
Nucro-Technics is a full-service Pharmaceutical Contract Support Organization that has completed projects for the ten largest pharmaceutical companies worldwide.  Nucro-Technics’ in-house services include: Pre-Clinical Toxicology; Genetic Toxicology; Bioanalytical Services; Chemistry/Microbiology Analysis & Method Development; and Quality Control/Quality Assurance/Regulatory Affairs consulting to the biotech, pharmaceutical and medical device industries. Read more at www.nucro-technics.com.

Contact:

Cambridge Healthtech Associates
Contact: Alison Serrano
Tel: + 1 (781) 972-5482
Email: aserrano@chacorporate.com

Nucro-Technics
Contact: Constantine Fanaras
Tel: +1 (416) 438-6727
Email: info@nucro-technics.com

Nucro-Technics has just received their Establishment Licence from Health Canada. It is available for download as a PDF on our Accreditations page.  As of 2012 Health Canada has changed the way that Establishment Licences will be issued.  New licences will not be issued automatically on an annual basis.  New licences will instead be issued when there is a change in the scope of the licence itself.  Please note that the most current version of the Establishment Licence will always be located on our accreditations page.

Nucro-Technics has just posted their Certificate of Recognition received from the Standards Council of Canada. It is available for download as a PDF on the Accreditations page.

This particular Certificate of Recognition came as a result of a three-day audit held earlier in 2011 by several inspectors from the Standards Council of Canada to ensure Nucro-Technics’ compliance with Good Laboratory Practice regulations.

Press Release

Nucro-Technics, a Contract Support Organization for the Pharmaceutical Industry, is announcing the development of a service with its Spanish partner, Anaxomics, to develop a set of screening assays to evaluate the potential safety of new drug candidates.  The outcome of this international partnership will be a rapid way for predicting the safety of new drug candidates and thus help companies make educated decisions during the drug development process in selecting promising compounds.

This development focuses on the problem plaguing the pharmaceutical industry where new molecular entity output remains constant, while research & development costs are steadily increasing.  As toxicity is one of the leading causes of drug attrition, this service will allow for the screening out of drug candidates that are likely to be toxic earlier in the drug development process.  This will allow for quicker selection of more promising candidates.

Upon completion of the development of this service, it will be possible to have a client’s drug candidate have its potential safety characterized, by an in-silico assay conducted by Anaxomics and an in-vivo assay using biomarkers, conducted by Nucro-Technics. The synergistic combination of these two assays will provide a highly accurate and cost-effective tool to help companies make educated decisions during the drug development process in selecting compounds that will meet the necessary safety requirements.

About Nucro-Technics:

Nucro-Technics is a full-service Contract Support Organization that has completed projects for the ten largest pharmaceutical companies worldwide.  Nucro-Technics’ in-house services include: Pre-Clinical Toxicology; Genetic Toxicology; Bioanalytical Services; Chemistry/Microbiology Analysis & Method Development; and Quality Control/Quality Assurance/Regulatory Affairs consulting to the biotech, pharmaceutical and medical device industries.

For further information, to receive a quotation, or to schedule a test, please contact NUCRO-TECHNICS.

In collaboration with the Consulate of Canada in Barcelona, Spain and Biocat, the Catalan Bioregion, Nucro-Technics was asked to present to a panel of Spanish and Ontario companies on the successes and challenges that it has had partnering with companies in Spain.

At the Discover Life Sciences 2010 Trade Mission, a group of Nucro-Technics employees had met with a Spanish company named Anaxomics.  As a result of this meeting, and with the support of the NRC Industrial Research Assistance Program, Nucro-Technics is currently running a research project with its Spanish partner to develop a set of screening assays to evaluate the potential safety of new drug candidates.  The outcome of this project will be a rapid way for predicting the safety of new drug candidates and thus help companies make educated decisions during the drug development process in selecting promising compounds.

Click here for a copy of the presentation that outlines the collaborative project.

Nucro-Technics is a full-service Contract Support Organization that has completed projects for the ten largest pharmaceutical companies worldwide.  Nucro-Technics’ in-house services include: Pre-Clinical Toxicology; Genetic Toxicology; Bioanalytical Services; Chemistry/Microbiology Analysis & Method Development; and Quality Control/Quality Assurance/Regulatory Affairs consulting to the biotech, pharmaceutical and medical device industries.

For further information, to receive a quotation, or to schedule a test, please contact NUCRO-TECHNICS.

NUCRO-TECHNICS’ Genetic Toxicology department has been busy validating numerous assays in response to what our customers have been requesting.  NUCRO-TECHNICS has been conducting Genetic Toxicology testing for over a decade now.  However, over the past 12 months, we’ve been expanding our service offerings in order to meet the needs of our Pharmaceutical and Biotech clients.  Full details on the assays that have been validated are available in the Genetic Toxicology section of our website.

For further information about these services, to receive a quotation, or to schedule a test, please contact NUCRO-TECHNICS.

Nucro-Technics has just received their 2011 Establishment License from Health Canada. It is available for download as a PDF on our Accreditations page.

Nucro-Technics has been invited to attend the BIOSPAIN 2010 Conference in Pamplona from September 29 – October 1, 2010. We are exhibiting with the National Research Council and will be available to answer questions as to how we can speed up your drug development.